Lundbeck Raises 2026 Outlook Again as Migraine Drug Vyepti Powers Earnings Beat
Direct answer
Danish drugmaker Lundbeck raised its full-year sales and profit forecasts for 2026 on Tuesday, November 10, 2026, after third-quarter earnings beat expectations. The main driver was strong demand in the United States for its migraine treatment Vyepti.
What happened
Lundbeck reported third-quarter revenue of 6.603 billion Danish kroner, up 7 percent at constant exchange rates and 5 percent in kroner from 6.279 billion kroner a year earlier. Reuters reported the results on November 10, and Inderes confirmed the same figures with extra detail from the company release.
Adjusted core earnings, a measure of underlying profit known as EBITDA, reached 2.261 billion kroner, about 339 million dollars. That was above the company-compiled consensus forecast of 1.95 billion kroner. Revenue also beat the consensus of 6.354 billion kroner, and adjusted earnings per share came in at 1.71 kroner against an expected 1.49 kroner.
Vyepti was the standout. Sales of the migraine drug rose 44 percent at constant currencies to 1.67 billion kroner in the quarter. Over the first nine months of 2026, Vyepti sales reached 4.533 billion kroner, up 45 percent at constant currencies.
The company raised its outlook for the full year. It now expects revenue growth of 11 percent to 12 percent at constant exchange rates, up from 7 percent to 9 percent before. It expects adjusted core earnings growth of 15 percent to 19 percent, up from 8 percent to 14 percent. This is the second time Lundbeck has raised its guidance this year, after an earlier upgrade in May.
Not every number moved up. Lundbeck lowered its 2026 profit margin forecast slightly, to 86 percent to 87 percent from around 87 percent, citing higher production costs.
Chief Executive Charl van Zyl said growth in the first nine months, led by Vyepti’s continued performance, supports the higher outlook.
Why it matters for beginners
When a company raises its forecast, it is telling investors it now expects to earn more than it previously thought. That usually happens because sales are stronger than expected, as they were here with Vyepti.
Three points matter for beginners.
First, one product can drive the whole story. Vyepti is a single drug, but its sales growth of more than 40 percent lifted the entire company. This is why investors watch which products a drugmaker depends on. A strong product is good news, but it also means the company relies heavily on it staying strong.
Second, a beat and a raise are different things. The beat is about the past quarter: results came in above forecasts. The raise is about the future: the company now expects a better full year. Lundbeck delivered both, which is why the market took notice.
Third, the warning still matters. Lundbeck said fourth-quarter revenue growth should moderate, because cheaper generic copies of its antidepressant Trintellix arrive from December, and competition for its antipsychotic drug Rexulti is intensifying. A higher forecast today does not mean every quarter will keep improving at the same pace.
For a related example of another drugmaker lifting its outlook this earnings season, see our earlier report: Amgen Raises 2026 Outlook as Q3 2026 Sales Rise
What to watch next
Watch Vyepti sales in the fourth quarter. If demand in the United States stays strong, the raised forecast should hold. If growth slows, the next update may be more cautious.
Also watch the generic competition for Trintellix starting in December. Generic copies usually cost far less, so sales of the original drug often fall quickly once they arrive. That is the main test of whether Lundbeck can keep growing in 2027.
More broadly, this is a useful reminder that a single company can depend on a small number of products. Spreading money across different companies and sectors, rather than betting on one, is one way beginners reduce that kind of risk: What Is Diversification, and Why Does It Matter?
Frequently asked questions
What is Lundbeck?
Lundbeck is a Danish drugmaker focused on brain health, including migraine, depression and schizophrenia treatments. Its best known products include the migraine drug Vyepti, the antidepressant Trintellix and the antipsychotic Rexulti.
What is Vyepti?
Vyepti is a migraine treatment given by infusion. It was the main growth driver in Lundbeck’s third-quarter results, with sales up 44 percent at constant currencies to 1.67 billion kroner in the quarter.
What did Lundbeck raise its forecast to?
The company now expects full-year revenue growth of 11 percent to 12 percent at constant exchange rates, up from 7 percent to 9 percent, and adjusted core earnings growth of 15 percent to 19 percent, up from 8 percent to 14 percent.
Why did the profit margin forecast fall if earnings beat expectations?
Lundbeck trimmed its 2026 profit margin forecast to 86 percent to 87 percent, from around 87 percent, because production costs are higher. Sales are growing faster than expected, but each sale is slightly less profitable than planned.
What could slow Lundbeck down next?
Generic competition for Trintellix starts in December, and competition for Rexulti is intensifying. Lundbeck expects fourth-quarter revenue growth to moderate for those reasons.
Sources
- Reuters, “Lundbeck hikes annual forecasts as migraine drug powers earnings beat“, November 10, 2026.
- Inderes, “Lundbeck: Q3 and upgraded guidance significantly above expectations”, November 10, 2026.
- Lundbeck, “Lundbeck raises full-year guidance as 9M revenue grows 13% CER“, November 10, 2026.
This article is for general information and education only. It is not legal or financial advice.
